Literature DB >> 23126403

Shortening baroreflex delay in hypertrophic cardiomyopathy patients -- an unknown effect of β-blockers.

Agnieszka Katarzynska-Szymanska1, Romuald Ochotny, Zofia Oko-Sarnowska, Hanna Wachowiak-Baszynska, Tomasz Krauze, Jaroslaw Piskorski, Adrian Gwizdala, Przemyslaw Mitkowski, Przemyslaw Guzik.   

Abstract

AIMS: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy and impaired diastolic and systolic function. Abnormal sympathetic-parasympathetic balance is a potential stimulus for left ventricular hypertrophy in HCM patients. β-Blockers are routinely used in HCM for their strong negative inotropic effect; however, these drugs also influence the sympathetic-parasympathetic balance. This study aimed to determine the autonomic control of the cardiovascular system and the autonomic effects of β-blockers in HCM patients treated or untreated with β-blockers.
METHODS: Among 51 HCM outpatients (18-70 years old; 29 men) there were 19 individuals with no medication and 32 subjects treated with a β-blocker. Fourteen age- and gender-matched (23-70 years old; nine men) healthy volunteers were enrolled in the control group. Continuous, non-invasive finger blood pressure was recorded during supine rest for 30 min. Autonomic regulation of the cardiovascular system was measured by heart rate variability and spontaneous baroreflex function (cross-correlation sequence method).
RESULTS: The mean pulse interval, time domain and spectral measures of heart rate variability and baroreflex sensitivity were comparable between HCM patients, treated or not with β-blockers, and the control group. However, the delay of the baroreflex was significantly longer in HCM patients who were not treated with β-blockers [2.0 (1.6-2.3) s] in comparison with HCM patients receiving β-blockers [1.4 (1.1-1.8) s; P = 0.0072] or control subjects [1.2 (0.8-1.8) s; P = 0.0025]. This delay did not differ between HCM patients treated with β-blockers and the control group.
CONCLUSIONS: Hypertrophic cardiomyopathy not treated with β-blockers is accompanied by prolonged baroreflex delay. The use of β-blockers normalizes this delay.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23126403      PMCID: PMC3690110          DOI: 10.1111/bcp.12027

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  48 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

2.  Time course analysis of baroreflex sensitivity during postural stress.

Authors:  Berend E Westerhof; Janneke Gisolf; John M Karemaker; Karel H Wesseling; Niels H Secher; Johannes J van Lieshout
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-07-21       Impact factor: 4.733

3.  [Spectrum analysis of heart rate variability in obstructive hypertrophic myocardiopathy. Evidence of altered autonomic function].

Authors:  U Limbruno; G Strata; G Mengozzi; R Baglini; A Di Vincenzo; G P Leoncini; M Mariani
Journal:  Cardiologia       Date:  1992-12

4.  Heart rate deceleration runs for postinfarction risk prediction.

Authors:  Przemyslaw Guzik; Jaroslaw Piskorski; Petra Barthel; Axel Bauer; Alexander Müller; Nadine Junk; Kurt Ulm; Marek Malik; Georg Schmidt
Journal:  J Electrocardiol       Date:  2011-09-14       Impact factor: 1.438

Review 5.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

6.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

7.  Assessment of heart rate variability in hypertrophic cardiomyopathy. Association with clinical and prognostic features.

Authors:  P J Counihan; L Fei; Y Bashir; T G Farrell; G A Haywood; W J McKenna
Journal:  Circulation       Date:  1993-10       Impact factor: 29.690

8.  Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.

Authors:  S M Heilbrunn; P Shah; M R Bristow; H A Valantine; R Ginsburg; M B Fowler
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

9.  Sympathetic restraint of baroreflex control of heart period in normotensive and hypertensive subjects.

Authors:  D Lucini; M Pagani; G S Mela; A Malliani
Journal:  Clin Sci (Lond)       Date:  1994-05       Impact factor: 6.124

10.  Temporal response patterns of the human sinus node to brief carotid baroreceptor stimuli.

Authors:  D L Eckberg
Journal:  J Physiol       Date:  1976-07       Impact factor: 5.182

View more
  2 in total

1.  Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy.

Authors:  David Dweck; Marcos A Sanchez-Gonzalez; Audrey N Chang; Raul A Dulce; Crystal-Dawn Badger; Andrew P Koutnik; Edda L Ruiz; Brittany Griffin; Jingsheng Liang; Mohamed Kabbaj; Frank D Fincham; Joshua M Hare; J Michael Overton; Jose R Pinto
Journal:  J Biol Chem       Date:  2014-06-27       Impact factor: 5.157

2.  Valsalva maneuver unveils central baroreflex dysfunction with altered blood pressure control in persons with a history of mild traumatic brain injury.

Authors:  Max J Hilz; Mao Liu; Julia Koehn; Ruihao Wang; Fabian Ammon; Steven R Flanagan; Katharina M Hösl
Journal:  BMC Neurol       Date:  2016-05-04       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.